SCHEMBL1011326

SCHEMBL1011326

CCOC(=O)Cc1ccc(OC)c(Oc2ccc(N)cc2CNCCC(=O)C2CC2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.41
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40
DRD2 P14416 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
CTSD P07339 1/20 0.36
TLR7 Q9NYK1 2/20 0.35
MAPK1 P28482 1/20 0.35
LMNA P02545 1/20 0.35
PPIB P23284 1/20 0.35
PPIA P62937 1/20 0.35
PPID Q08752 1/20 0.35
PPIG Q13427 1/20 0.35
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA9 Q16790 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1944236 0.87 ALDH1A1 (0.42) POLBMEN1ALDH1A1KMT2AATM
SCHEMBL1943649 0.86 CYP3A4 (0.52) POLBMEN1ALDH1A1KMT2AATM
SCHEMBL1944250 0.84 KMT2A (0.43) POLBMEN1ALDH1A1KMT2AL3MBTL1
SCHEMBL1944128 0.83 PTGDR2 (0.45) POLBMEN1ALDH1A1KMT2AL3MBTL1
SCHEMBL1011325 0.80 PTGDR2 (0.49) POLBMEN1ALDH1A1KMT2AATM
SCHEMBL149777 0.79 PTGDR2 (0.40) POLBMEN1ALDH1A1KMT2AATM
SCHEMBL13521900 0.78 L3MBTL1 (0.41) POLBMEN1ALDH1A1KMT2AATM
SCHEMBL137203 0.78 PTGDR2 (0.47) KMT2A
SCHEMBL154285 0.78 PTGDR2 (0.44) POLBMEN1ALDH1A1KMT2AATM
SCHEMBL3387106 0.76 PTGDR2 (0.37) POLBMEN1ALDH1A1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426449-B2 Aminoalkylphenyl antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2013-04-23 US disclosed
US-20110130453-A1 AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-06-02 US disclosed
EP-2268611-A2 AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS Amira Pharmaceuticals, Inc. (US) 2011-01-05 EP disclosed
WO-2009145989-A2 AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130453-A1 AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 POLB 2927/4885MEN1 4863/4885ALDH1A1 1769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.